JP2016500111A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016500111A5 JP2016500111A5 JP2015544191A JP2015544191A JP2016500111A5 JP 2016500111 A5 JP2016500111 A5 JP 2016500111A5 JP 2015544191 A JP2015544191 A JP 2015544191A JP 2015544191 A JP2015544191 A JP 2015544191A JP 2016500111 A5 JP2016500111 A5 JP 2016500111A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- hydrogen
- hydroxyl
- disease
- pulmonary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 15
- 208000019693 Lung disease Diseases 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 210000004072 lung Anatomy 0.000 claims description 8
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 8
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims description 6
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims description 6
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- 206010014561 Emphysema Diseases 0.000 claims description 4
- 206010069351 acute lung injury Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 claims description 2
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 208000037357 HIV infectious disease Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000011623 Obstructive Lung disease Diseases 0.000 claims description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 208000018578 heart valve disease Diseases 0.000 claims description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000001797 obstructive sleep apnea Diseases 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 159000000000 sodium salts Chemical group 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 24
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261730749P | 2012-11-28 | 2012-11-28 | |
| US61/730,749 | 2012-11-28 | ||
| PCT/US2013/072038 WO2014085474A1 (en) | 2012-11-28 | 2013-11-26 | Treatment of pulmonary disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016500111A JP2016500111A (ja) | 2016-01-07 |
| JP2016500111A5 true JP2016500111A5 (enExample) | 2017-01-12 |
| JP6270171B2 JP6270171B2 (ja) | 2018-01-31 |
Family
ID=49753520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015544191A Expired - Fee Related JP6270171B2 (ja) | 2012-11-28 | 2013-11-26 | 肺疾患の処置 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20140148428A1 (enExample) |
| EP (1) | EP2925328A1 (enExample) |
| JP (1) | JP6270171B2 (enExample) |
| KR (1) | KR102106186B1 (enExample) |
| CN (1) | CN104853758A (enExample) |
| AU (1) | AU2013352288B2 (enExample) |
| BR (1) | BR112015012312A2 (enExample) |
| CA (1) | CA2891348C (enExample) |
| CL (1) | CL2015001442A1 (enExample) |
| HK (1) | HK1211844A1 (enExample) |
| IL (1) | IL239025B (enExample) |
| MX (1) | MX2015006710A (enExample) |
| MY (1) | MY170802A (enExample) |
| NZ (1) | NZ708501A (enExample) |
| PH (1) | PH12015501108B1 (enExample) |
| RU (1) | RU2693382C2 (enExample) |
| SG (1) | SG11201503697TA (enExample) |
| TW (1) | TWI636786B (enExample) |
| WO (1) | WO2014085474A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3071696T1 (sl) | 2013-11-22 | 2019-11-29 | Mina Therapeutics Ltd | C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe |
| WO2016045480A1 (zh) * | 2014-09-28 | 2016-03-31 | 上海源力生物技术有限公司 | 一种奥贝胆酸的制备方法 |
| EA033427B1 (ru) * | 2014-11-19 | 2019-10-31 | Nzp Uk Ltd | 6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
| ES2748692T3 (es) * | 2014-11-19 | 2020-03-17 | Nzp Uk Ltd | Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la producción de moduladores FXR de esteroides |
| KR102526632B1 (ko) * | 2014-11-19 | 2023-04-27 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 5β-6-알킬-7-하이드록시-3-온 스테로이드 |
| JP6698085B2 (ja) * | 2014-11-19 | 2020-05-27 | エヌゼットピー ユーケー リミテッド | ステロイドＦＸＲモジュレーター製造のための中間体としての６α−アルキル−６，７−ジオン−ステロイド |
| CN105348365A (zh) * | 2014-12-03 | 2016-02-24 | 四川百利药业有限责任公司 | 一种胆酸衍生物及其制备方法、药物组合物和用途 |
| CN105801653B (zh) * | 2014-12-30 | 2018-04-17 | 苏州晶云药物科技有限公司 | 奥贝胆酸的晶型a及其制备方法 |
| CZ2015504A3 (cs) * | 2015-07-16 | 2017-01-25 | Zentiva, K.S. | Krystalické formy obeticholové kyseliny |
| CN105085597B (zh) * | 2015-08-28 | 2017-03-29 | 成都百裕制药股份有限公司 | 一种无定型奥贝胆酸的制备方法 |
| KR20180052756A (ko) | 2015-09-24 | 2018-05-18 | 인터셉트 파마슈티컬즈, 인크. | 담즙산 유도체 제조를 위한 방법 및 중간체 |
| EP3359160B1 (en) * | 2015-10-07 | 2021-08-25 | Intercept Pharmaceuticals, Inc. | Farnesoid x receptor modulators |
| CN106589039B (zh) * | 2015-10-15 | 2019-12-17 | 苏州朗科生物技术股份有限公司 | 一种奥贝胆酸的制备方法及相关化合物 |
| CN106589038A (zh) * | 2015-10-15 | 2017-04-26 | 重庆医药工业研究院有限责任公司 | 一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法 |
| CN106668027A (zh) * | 2015-11-05 | 2017-05-17 | 中美华世通生物医药科技（武汉）有限公司 | 奥贝胆酸药物组合物及其制备方法 |
| CN105399793A (zh) * | 2015-12-24 | 2016-03-16 | 北京康立生医药技术开发有限公司 | 一种胆烷酸的制备方法 |
| WO2017137931A1 (en) | 2016-02-10 | 2017-08-17 | Dr. Reddy’S Laboratories Limited | Amine salt of obeticholic acid |
| JPWO2017170858A1 (ja) * | 2016-03-31 | 2019-02-14 | インターセプト ファーマシューティカルズ， インコーポレイテッド | 溶出性に優れた経口製剤 |
| CA3020698A1 (en) * | 2016-04-13 | 2017-10-19 | Intercept Pharmaceuticals, Inc. | Methods of treating or preventing hepatocellular carcinoma |
| GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
| GB201608776D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| EP3464316A4 (en) * | 2016-06-01 | 2020-02-19 | Dr. Reddy's Laboratories Ltd. | PROCESS FOR THE PREPARATION OF OBETICHOLIC ACID |
| CN106046095B (zh) * | 2016-06-06 | 2017-02-22 | 南京理工大学 | 奥贝胆酸的合成方法 |
| CN109963567A (zh) * | 2016-09-30 | 2019-07-02 | 英特塞普特医药品公司 | 胆汁酸衍生物的结晶形式 |
| CN108117579A (zh) * | 2016-11-29 | 2018-06-05 | 昆明积大制药股份有限公司 | 奥贝胆酸及其中间体的制备方法 |
| TW201832768A (zh) * | 2017-03-07 | 2018-09-16 | 英特賽普醫藥品公司 | 治療癌症的方法 |
| WO2019048632A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE |
| KR20190030805A (ko) * | 2017-09-14 | 2019-03-25 | 경상대학교산학협력단 | 폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법 |
| WO2019085963A1 (zh) * | 2017-11-02 | 2019-05-09 | 正大天晴药业集团股份有限公司 | 一种胆酸类化合物的制备方法 |
| US12168012B2 (en) | 2018-07-25 | 2024-12-17 | Novartis Ag | NLRP3 inflammasome inhibitors |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| TW202122078A (zh) | 2019-09-06 | 2021-06-16 | 瑞士商諾華公司 | 使用lta4h抑制劑治療肝臟疾病之方法 |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| CN113318114B (zh) | 2020-02-28 | 2023-02-17 | 广州市赛普特医药科技股份有限公司 | 小分子化合物在治疗肺上皮细胞损伤和/或血管内皮细胞损伤介导的疾病中的用途 |
| MX2022010548A (es) | 2020-02-28 | 2022-09-23 | Kallyope Inc | Agonistas de gpr40. |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| WO2026133229A1 (en) | 2024-12-20 | 2026-06-25 | Novartis Ag | Nlrp3 inflammasome inhibitors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CY1308A (en) | 1979-12-06 | 1985-12-06 | Glaxo Group Ltd | Device for dispensing medicaments |
| US4353656A (en) | 1980-10-14 | 1982-10-12 | Xerox Corporation | Moving coil, multiple energy print hammer system including a closed loop servo |
| EP0069715B1 (en) | 1981-07-08 | 1986-11-05 | Aktiebolaget Draco | Powder inhalator |
| DK172541B1 (da) | 1982-10-08 | 1998-12-07 | Glaxo Group Ltd | Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
| AU591152B2 (en) | 1985-07-30 | 1989-11-30 | Glaxo Group Limited | Devices for administering medicaments to patients |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| US5977095A (en) * | 1993-03-09 | 1999-11-02 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome |
| JPH11501892A (ja) | 1995-03-10 | 1999-02-16 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | エアロゾルバルブ |
| GB9700226D0 (en) | 1997-01-08 | 1997-02-26 | Glaxo Group Ltd | Inhalation device |
| US6632666B2 (en) | 2000-01-14 | 2003-10-14 | Biolife Solutions, Inc. | Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media |
| DK1392714T3 (da) * | 2001-03-12 | 2006-01-09 | Intercept Pharmaceuticals Inc | Steroider som agonister for FXR |
| EP1696910A4 (en) * | 2003-09-26 | 2009-12-09 | Smithkline Beecham Corp | COMPOSITIONS AND METHOD FOR THE TREATMENT OF FIBROSIS |
| WO2005089316A2 (en) | 2004-03-12 | 2005-09-29 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using fxr ligands |
| ITMI20050912A1 (it) * | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| DK2040713T3 (da) | 2006-06-27 | 2014-09-29 | Intercept Pharmaceuticals Inc | Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande |
| BRPI0713946A2 (pt) * | 2006-06-29 | 2012-12-04 | Hoffmann La Roche | compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de fxr, e uso dos compostos |
| US8796249B2 (en) * | 2008-07-30 | 2014-08-05 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
| AU2009316484B2 (en) * | 2008-11-19 | 2015-04-16 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
| WO2010069604A1 (en) * | 2008-12-19 | 2010-06-24 | Royal College Of Surgeons In Ireland | Treatment of diarrhoea |
| CN102712672B (zh) * | 2009-08-25 | 2016-09-14 | 胆清医药有限公司 | 用于治疗胆疾病的多羟基化胆汁酸 |
| US9416151B2 (en) * | 2010-08-25 | 2016-08-16 | Lurong ZHANG | Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis |
| ES2822375T3 (es) * | 2012-06-19 | 2021-04-30 | Intercept Pharmaceuticals Inc | Preparación de la forma no cristalina del ácido obeticólico |
-
2013
- 2013-11-26 WO PCT/US2013/072038 patent/WO2014085474A1/en not_active Ceased
- 2013-11-26 MX MX2015006710A patent/MX2015006710A/es active IP Right Grant
- 2013-11-26 HK HK15112720.5A patent/HK1211844A1/xx unknown
- 2013-11-26 NZ NZ708501A patent/NZ708501A/en not_active IP Right Cessation
- 2013-11-26 CN CN201380061734.4A patent/CN104853758A/zh active Pending
- 2013-11-26 JP JP2015544191A patent/JP6270171B2/ja not_active Expired - Fee Related
- 2013-11-26 BR BR112015012312A patent/BR112015012312A2/pt not_active Application Discontinuation
- 2013-11-26 MY MYPI2015001342A patent/MY170802A/en unknown
- 2013-11-26 KR KR1020157016809A patent/KR102106186B1/ko not_active Expired - Fee Related
- 2013-11-26 RU RU2015122027A patent/RU2693382C2/ru active
- 2013-11-26 AU AU2013352288A patent/AU2013352288B2/en not_active Ceased
- 2013-11-26 SG SG11201503697TA patent/SG11201503697TA/en unknown
- 2013-11-26 CA CA2891348A patent/CA2891348C/en active Active
- 2013-11-26 US US14/090,815 patent/US20140148428A1/en not_active Abandoned
- 2013-11-26 EP EP13802822.0A patent/EP2925328A1/en not_active Withdrawn
- 2013-11-27 TW TW102143227A patent/TWI636786B/zh not_active IP Right Cessation
-
2015
- 2015-05-19 PH PH12015501108A patent/PH12015501108B1/en unknown
- 2015-05-27 IL IL239025A patent/IL239025B/en active IP Right Grant
- 2015-05-27 CL CL2015001442A patent/CL2015001442A1/es unknown
-
2016
- 2016-01-28 US US15/008,665 patent/US20160213689A1/en not_active Abandoned
-
2017
- 2017-07-18 US US15/652,777 patent/US20180064729A1/en not_active Abandoned